Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases

Mucci, Armida; Merlotti, E.; Üçok, Alp; Alemán, André; Galderisi, Silvana

doi:10.1016/j.schres.2016.05.014

Cited by 116 publications

(98 citation statements)

References 169 publications

(254 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PANSS score was derived dominantly from the negative items of the scale. Overall, her negative symptoms fulfilled criteria for predominantly negative symptoms, meaning that positive symptomatology was reduced, while negative symptoms were more explicit and dominated the clinical picture (Riedel et al, 2005;Olie et al, 2006;Mucci et al, 2017). Baseline rating scale sores are presented in Table 1.…”

Section: Case Descriptionmentioning

confidence: 99%

Early-Onset Schizophrenia With Predominantly Negative Symptoms: A Case Study of a Drug-Naive Female Patient Treated With Cariprazine

et al. 2020

View full text Add to dashboard Cite

Section: Case Descriptionmentioning

confidence: 99%

Early-Onset Schizophrenia With Predominantly Negative Symptoms: A Case Study of a Drug-Naive Female Patient Treated With Cariprazine

et al. 2020

View full text Add to dashboard Cite

“…This reduction in goal-directed behaviour hampers daily life functioning and interferes with the recovery process [2-5]. The distinction between primary negative symptoms, a core aspect of the illness, and secondary negative symptoms bears important therapeutic implications [6]. Primary negative symptoms comprise the core features intrinsic to schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

Improving Pleasure and Motivation in Schizophrenia: A Randomized Controlled Clinical Trial

Favrod

Nguyen

Chaix

et al. 2019

Psychother Psychosom

View full text Add to dashboard Cite

Background: Negative symptoms are frequent in patients with schizophrenia and are associated with marked impairments in social functioning. The efficacy of drug-based treatments and psychological interventions on primary negative symptoms remains limited. The Positive Emotions Programme for Schizophrenia (PEPS) is designed to improve pleasure and motivation in schizophrenia patients by targeting emotion regulation and cognitive skills relevant to apathy and anhedonia. The main hypothesis of this study is that patients who attend 8 one-hour sessions of PEPS and treatment as usual (TAU) will have lower total apathy-avolition and anhedonia-asociality composite scores on the Scale for the Assessment of Negative Symptoms (SANS) than patients who attend only TAU. Methods: Eighty participants diagnosed with schizophrenia or schizoaffective disorder were randomized to receive either TAU or PEPS + TAU. The participants were assessed by independent evaluators before randomization (T0), in a post-test after 8 weeks of treatment (T1) and at a 6-month follow-up (T2). Results: The post-test results and 6-month follow-up assessments according to an intention-to-treat analysis showed that the apathy and anhedonia composite scores on the SANS indicated statistically greater clinical improvements in PEPS participants than in non-PEPS participants. In the post-test, anhedonia but not apathy was significantly improved, thus favouring the PEPS condition. These results were sustained at the 6-month follow-up. Conclusions: PEPS is an effective intervention to reduce anhedonia in schizophrenia. PEPS is a short, easy-to-use, group-based, freely available intervention that is easy to implement in a variety of environments (ClinicalTrials.gov ID: NCT02593058).

show abstract

“…They are frequently observed and have a strong impact on functional outcome (4,5). However, the construct of negative symptoms has evolved over the last decades and a substantial heterogeneity is increasingly acknowledged with respect to impact on functional outcome, treatment availability and pathophysiological mechanisms (6)(7)(8). Studies in the last two decades contributed to single out main sources of heterogeneity (8,9).…”

Section: Reviewmentioning

confidence: 99%

Aetiopathological mechanisms of negative symptoms in schizophrenia

Galderisi¹,

Caputo²,

Giordano³

et al. 2016

Die Psychiatrie

View full text Add to dashboard Cite

Summary Background: Negative symptoms represent core features of schizophrenia and have an unfavorable impact on the disease outcome. Unfortunately, their aetiopathology has not been elucidated yet and the effectiveness of available treatments is not satisfactory. Aims: This review aims to provide a critical overview of research findings concerning negative symptom aetiopathology, highlighting limitations and future perspectives. Results: Enduring and transient negative symptoms, as well as motivation-related and expression-related domains of negative symptoms, have different risk factors and clinical correlates, and are associated to distinct brain abnormalities. Enduring negative symptoms seem to be related to subtle, pervasive deviations in neurodevelopmental trajectories. Expression deficit, as compared with avolition, shows a stronger association with neurological soft signs, cognitive impairment and diffuse disconnectivity. Avolition/apathy is a multifaceted construct probably related to deficits of reward and action valuation and instrumental learning, subtended by cortico-striatal dysfunctions. Conclusions: Research findings support the heterogeneity of negative symptoms and are likely to pave the way for the discovery of more effective treatments.

show abstract

Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases

Cited by 116 publications

References 169 publications

Early-Onset Schizophrenia With Predominantly Negative Symptoms: A Case Study of a Drug-Naive Female Patient Treated With Cariprazine

Early-Onset Schizophrenia With Predominantly Negative Symptoms: A Case Study of a Drug-Naive Female Patient Treated With Cariprazine

Improving Pleasure and Motivation in Schizophrenia: A Randomized Controlled Clinical Trial

Aetiopathological mechanisms of negative symptoms in schizophrenia

Contact Info

Product

Resources

About